Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled AAT for Emphysema in Alpha-1 Antitrypsin Deficiency
NCT01217671Phase 3Completed
- Sponsor
- Kamada Ltd.
- Start
- Dec 2009
- Primary completion
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of alpha1-proteinase inhibitor (human) in alpha-1 antitrypsin deficiency (AATD), sponsored by Kamada Ltd.. Started Dec 2009; status: completed.
02
Drugs
alpha1-proteinase inhibitor (human)
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT01217671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217671.